Apomorphine-Induced Prepulse Inhibition Disruption is Associated with a Paradoxical Enhancement of Prepulse Stimulus Reactivity

被引:0
|
作者
Benjamin K Yee
Holger Russig
Joram Feldon
机构
[1] Laboratory of Behavioural Neurobiology,
[2] Swiss Federal Institute of Technology,undefined
来源
Neuropsychopharmacology | 2004年 / 29卷
关键词
amphetamine; apomorphine; haloperidol; mice; prepulse inhibition; schizophrenia; startle;
D O I
暂无
中图分类号
学科分类号
摘要
Prepulse inhibition (PPI) refers to the reduction in startle reaction to a startle-eliciting stimulus when it is shortly preceded by a subthreshold prepulse stimulus. PPI has been extensively employed as an assay for sensorimotor gating, and its disruption has been characterized in specific disease conditions, including schizophrenia. In animals, dopamine agonists disrupt PPI, and this disruption can be antagonized by antipsychotic drug treatment. The present study extended these fundamental findings to C57BL6 mice, and further evaluated the subjects' reaction to the prepulse stimulus alone in relation to the expression of PPI. Not only did apomorphine (2.0 mg/kg, intraperitoneal (i.p.)) attenuate PPI but it also enhanced reactivity to the prepulse stimulus. The dual effects of apomorphine appear paradoxical in view of the positive correlation, detectable in both the control and apomorphine groups, between prepulse reactivity and PPI magnitude. The present findings contradict the hypothesis that apomorphine disrupts PPI via reduced detectability or perception of the prepulse, and we further propose that enhanced distractibility may provide a parsimonious account for the dual effects of apomorphine. Moreover, haloperidol pretreatment (0.4 mg/kg, i.p.) fully antagonized the effects of apomorphine upon prepulse reactivity as well as on PPI. The present results add to our understanding of the relevance and applicability of the PPI paradigm in modeling schizophrenia-like symptoms in animals.
引用
收藏
页码:240 / 248
页数:8
相关论文
共 50 条
  • [41] Cannabidiol Reverses MK-801-Induced Disruption of Prepulse Inhibition in Mice
    Leonora E Long
    Daniel T Malone
    David A Taylor
    Neuropsychopharmacology, 2006, 31 : 795 - 803
  • [42] Finasteride administration potentiates the disruption of prepulse inhibition induced by forced swim stress
    Pallares, M.
    Llido, A.
    Modol, L.
    Vallee, M.
    Darbra, S.
    BEHAVIOURAL BRAIN RESEARCH, 2015, 289 : 55 - 60
  • [43] On the influence of baseline startle reactivity on the indexation of prepulse inhibition
    Csomor, Philipp A.
    Vollenweider, Franz X.
    Nicolet, Tiana
    Yee, Benjamin K.
    Feldon, Joram
    Quednow, Boris B.
    BEHAVIORAL NEUROSCIENCE, 2008, 122 (04) : 885 - 900
  • [44] INHIBITION OF APOMORPHINE-INDUCED VOMITING BY BENZQUINAMIDE
    KLEIN, RL
    GRAVES, CL
    KIM, YI
    BLATNICK, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1970, 11 (04) : 530 - &
  • [45] Nitric oxide synthase inhibitors attenuate phencyclidine-induced disruption of prepulse inhibition
    Wiley, JL
    NEUROPSYCHOPHARMACOLOGY, 1998, 19 (01) : 86 - 94
  • [46] Nitric oxide synthase inhibitors attenuate phencyclidine-induced disruption of prepulse inhibition
    Wiley J.L.
    Neuropsychopharmacology, 1998, 19 (1) : 86 - 94
  • [47] THE ATYPICAL ANTIPSYCHOTIC, REMOXIPRIDE, BLOCKS PHENCYCLIDINE-INDUCED DISRUPTION OF PREPULSE INHIBITION IN THE RAT
    JOHANSSON, C
    JACKSON, DM
    SVENSSON, L
    PSYCHOPHARMACOLOGY, 1994, 116 (04) : 437 - 442
  • [48] Isolation rearing-induced disruption of prepulse inhibition: further evidence for fragility of the response
    Weiss, IC
    Feldon, J
    Domeney, AM
    BEHAVIOURAL PHARMACOLOGY, 1999, 10 (02): : 139 - 149
  • [49] Nitric oxide modulation of methylphenidate-induced disruption of prepulse inhibition in Swiss mice
    Issy, A. C.
    Salum, C.
    Del Bel, E. A.
    BEHAVIOURAL BRAIN RESEARCH, 2009, 205 (02) : 475 - 481
  • [50] The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice
    Kim Fejgin
    Sergej Safonov
    Erik Pålsson
    Caroline Wass
    Jörgen A. Engel
    Lennart Svensson
    Daniel Klamer
    Psychopharmacology, 2007, 191 : 377 - 385